From £6.99 per month
ShareProphets
The one stop source for breaking news, expert analysis, and podcasts on fast-moving AIM and LSE listed shares

MINDING THE LSE’S BUSINESS

Join for as low as £6.99 per month

With ShareProphets’ membership, you receive:

• All premium articles

• Tom Winnifrith’s Bearcast

• Access to all the entire nearly 10 year archive

• ShareProphets Daily Newsletter

Results: CEL

Search articles by EPIC code
EPIC CEL
views

Celadon Pharma is on a nutso valuation, it is dangerous but surely it is a short

Back on March 23 I did a bearcast on Celadon Pharma (CEL) HERE which initially saw the shares marked lower from 125p to c105p. But the company fought back with private briefings. It did not draw attention to my well founded misgivings by issuing an RNS “refuting” what I said. That was a smart move. Instead someone roped in the serial liar John Story to do a mass new media spam pushing the shares, the CEO also did a Proactive interview and, for a while it worked. The shares hit 180p. Ouch. But then they started slipping.

Page 1 of 1 (2 articles)
Subscribe to our newsletter

Daily digest of our latest stories.



Search ShareProphets

Complete Coverage

Recent Comments